Five corporations dominate the global tobacco market. Together they manufacture the vast majority of the world's cigarettes, control hundreds of subsidiaries across more than 180 countries, and collectively generate revenues exceeding $130 billion per year. They also share a common strategy: lobbying regulators, funding allied organisations, placing former employees in key institutions, and positioning their brands as agents of "harm reduction" — while continuing to sell cigarettes in every market they can reach.
Philip Morris International is the world's largest international tobacco company by market share — a position built almost entirely on Marlboro, the best-selling cigarette brand globally since the 1970s. Spun off from Altria Group in 2008, PMI operates outside the United States, selling products in approximately 170 markets.
PMI's central strategic narrative today revolves around its smoke-free transition. The company invested over $14 billion since 2008 to develop IQOS, its heat-not-burn device, which holds approximately 77% of the global heat-not-burn market. By 2025, smoke-free products accounted for 42% of PMI's total net revenues — nearly $17 billion. In Japan alone, IQOS reached a record 32.2% share of the combined cigarette and heated tobacco unit market.
PMI also acquired Swedish Match in 2022 for $16 billion, gaining control of ZYN, the world's leading nicotine pouch brand. This acquisition cemented PMI's position across all major nicotine product categories.
Despite the "smoke-free future" rhetoric, PMI continued to grow its cigarette volumes in markets where heat-not-burn is not permitted — including Turkey, India, Brazil and Vietnam. Its international market share grew from 28.6% in 2023 to 29.2% in 2025, driven by both pricing and volume.
British American Tobacco is one of the oldest and most geographically diversified tobacco corporations in the world, with operations across more than 180 countries. Founded in 1902 as a joint venture between Imperial Tobacco and the American Tobacco Company, BAT grew through successive acquisitions to become a true global heavyweight.
Its largest single market today is the United States, which it entered in full through the $49.4 billion acquisition of Reynolds American in 2017 — the largest deal in tobacco history. That acquisition gave BAT control of Newport, the top-selling menthol cigarette in the US, along with several other major American brands.
BAT's smoke-free portfolio is built around three flagship platforms: Vuse for e-vapor, glo for heated tobacco, and Velo for nicotine pouches. New categories revenue grew to £3.62 billion in 2025, up 7% year-on-year, with Velo reaching the number two position in volume and value share in the US within a year of launching its updated Velo Plus format.
BAT has faced significant litigation exposure in Canada, where it settled all pending tobacco-related lawsuits alongside JTI and Imperial Brands — a process that resulted in a provision of hundreds of millions in 2024.
Japan Tobacco International is the international tobacco arm of Japan Tobacco Inc. (JT Group), a company founded in 1904 as a Japanese government monopoly. The Japanese government retains approximately 33% ownership — a detail of considerable political relevance when analysing JTI's lobbying posture at both national and international levels.
JTI built its international presence through a series of major acquisitions: RJR International from R.J. Reynolds (1999), Gallaher Group (2007, for £7.5 billion), and most recently Vector Group (2024, $2.4 billion) — a deal that increased JTI's US market share from approximately 2.3% to around 8%.
JTI's reduced-risk product strategy centres on Ploom, its heat-not-burn platform, which reached 24 markets by end of 2024 with a target of 40 markets by 2026. In Japan, the most mature HTS market globally, Ploom reached a 12.7% segment share in Q1 2025. JTI also markets Logic in the e-vapor segment.
JTI operates globally through dozens of national subsidiaries, and its lobbying activities have attracted scrutiny across multiple markets. A UN report in 2019 linked JTI to companies associated with violations of international human rights law in Myanmar.
Imperial Brands is the smallest of the Big Five — a position the company itself acknowledges, describing its strategy as that of a "challenger" relative to larger competitors. Founded in 1901 as Imperial Tobacco Company, it has operated under the Imperial Brands name since 2016.
Imperial's portfolio is built around a core of heritage brands — notably Davidoff, Gauloises, West and Fortuna — alongside the iconic rolling papers brand Rizla and the US cigar brand Backwoods. In the US market, its cigarette presence relies heavily on Winston and Kool.
The company's next-generation product strategy includes blu (e-vapor), Pulze (heated tobacco) and Zone X (nicotine pouches). NGP net revenue grew 13.7% in FY2025, driven primarily by oral nicotine in the US and Europe. Imperial also owns Logista, a major European distribution and logistics network that serves tobacco and other consumer goods.
Imperial was involved in the major Canadian litigation settlement concluded in 2025, alongside BAT and JTI, covering all pending tobacco-related health claims in the country.
Altria Group is the US domestic counterpart of PMI — the company from which PMI was spun off in 2008. Operating exclusively in the United States, Altria is the dominant player in the American cigarette market, with approximately 48% market share built almost entirely on the strength of Marlboro, the best-selling cigarette brand in the US for decades.
Altria's history is marked by a series of high-profile — and frequently costly — strategic pivots in the smoke-free space. The company held a major stake in JUUL Labs, the e-cigarette startup, which it wrote down almost entirely following regulatory setbacks. It then sold the US commercialization rights for IQOS back to PMI in 2024, booking a significant gain on the transaction.
Its current smoke-free strategy rests on NJOY, an e-vapor brand acquired in 2023, and its oral tobacco products portfolio — particularly on! nicotine pouches and the legacy moist snuff brands Copenhagen and Skoal.
As the principal US tobacco lobby, Altria has historically been one of the most active corporate actors in American regulatory and political affairs, spending tens of millions of dollars annually on federal lobbying and political contributions.
Despite competing commercially, the five majors share a common playbook when it comes to protecting their interests — a set of documented strategies deployed across regulatory environments, scientific institutions, civil society and governments worldwide.
Industry-funded organisations presenting themselves as independent voices in public health debates — think tanks, consumer associations, harm reduction coalitions — often without disclosing their funding sources.
Systematic placement of former government officials, regulators and public health figures into industry roles — and recruitment of former industry employees into regulatory bodies. Documented across the EU, UK and US.
Funding researchers, academic institutions and scientific journals to produce results favourable to industry products. The practice, pioneered in the 1950s to cast doubt on the smoking-cancer link, continues in updated forms.
Direct engagement with legislators and regulators — declared in transparency registers, but often complemented by indirect channels through trade associations, consultancies and think tanks.
Presenting smoke-free products (e-cigarettes, heated tobacco, pouches) as public health tools while simultaneously selling cigarettes in markets where these products are absent or restricted.
Using legal resources to challenge regulations, delay implementation, and deter governments — particularly in lower-income countries — from enacting tobacco control measures.
Leveraging bilateral trade agreements to challenge tobacco packaging and advertising laws as barriers to trade — with cases brought against Australia, Uruguay and others.
As markets in high-income countries shrink under regulation, intensive marketing and lobbying efforts increasingly target low- and middle-income countries, particularly in Africa and Southeast Asia.
Tobacco Nexus documents over 2,900 entities — subsidiaries, lobbyists, front groups, allied organisations and individuals — connected to these five corporations.
Request database access → About the project